Company intelligence / Profile preview
Eternity Bioscience Inc.
Cranbury, New Jersey, United Stateseternitybioscience.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
The company has multiple programs in development, with their BTK inhibitor program reaching Phase 2 clinical trials. Their EZH2 inhibitor program has reached NDA/BLA stage. Several other programs are in preclinical development.
- Therapeutic areas
- OncologyDermatologyMetabolic DisordersCardiovascular
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TGTX (licensed two BTK inhibitors for a total value of $347 million)
Beyond the preview
Go deeper on Eternity Bioscience Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eternity Bioscience Inc..